KR20140067102A - 선택적 안드로겐 수용체 조절제 - Google Patents

선택적 안드로겐 수용체 조절제 Download PDF

Info

Publication number
KR20140067102A
KR20140067102A KR1020147009338A KR20147009338A KR20140067102A KR 20140067102 A KR20140067102 A KR 20140067102A KR 1020147009338 A KR1020147009338 A KR 1020147009338A KR 20147009338 A KR20147009338 A KR 20147009338A KR 20140067102 A KR20140067102 A KR 20140067102A
Authority
KR
South Korea
Prior art keywords
methyl
mmol
compound
amino
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147009338A
Other languages
English (en)
Korean (ko)
Inventor
프라바카르 콘다지 자다브
아쉬라프 사이드
조나단 에드워드 그린
벤카테쉬 크리쉬난
도날드 폴 매튜즈
그레고리 알란 스티븐슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140067102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20140067102A publication Critical patent/KR20140067102A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147009338A 2011-10-13 2012-10-05 선택적 안드로겐 수용체 조절제 Abandoned KR20140067102A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13
US61/546,711 2011-10-13
PCT/US2012/058824 WO2013055577A1 (en) 2011-10-13 2012-10-05 Selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
KR20140067102A true KR20140067102A (ko) 2014-06-03

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009338A Abandoned KR20140067102A (ko) 2011-10-13 2012-10-05 선택적 안드로겐 수용체 조절제

Country Status (28)

Country Link
US (1) US8658693B2 (enExample)
EP (1) EP2766350B1 (enExample)
JP (1) JP6002228B2 (enExample)
KR (1) KR20140067102A (enExample)
CN (1) CN103842348B (enExample)
AP (1) AP2014007548A0 (enExample)
AR (1) AR088082A1 (enExample)
AU (1) AU2012321113B2 (enExample)
BR (1) BR112014008668A2 (enExample)
CA (1) CA2847889A1 (enExample)
CL (1) CL2014000895A1 (enExample)
CO (1) CO6910195A2 (enExample)
CR (1) CR20140156A (enExample)
DO (1) DOP2014000075A (enExample)
EA (1) EA201490519A1 (enExample)
EC (1) ECSP14013305A (enExample)
ES (1) ES2626820T3 (enExample)
GT (1) GT201400067A (enExample)
IL (1) IL231440A0 (enExample)
MX (1) MX2014004558A (enExample)
PE (1) PE20141669A1 (enExample)
PH (1) PH12014500808A1 (enExample)
PL (1) PL2766350T3 (enExample)
PT (1) PT2766350T (enExample)
SG (1) SG11201401794YA (enExample)
TN (1) TN2014000136A1 (enExample)
TW (1) TWI449686B (enExample)
WO (1) WO2013055577A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
US10093660B2 (en) 2013-12-04 2018-10-09 Evotec Internatonal Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
PL3507289T3 (pl) 2016-09-02 2021-01-25 Suven Life Sciences Limited Dodatnie allosteryczne modulatory receptora muskarynowego m1
EP3684761A1 (en) 2017-09-18 2020-07-29 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
JP7778095B2 (ja) * 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE602006003432D1 (de) * 2005-05-13 2008-12-11 Lilly Co Eli Latoren des androgenrezeptors
BRPI0619208A2 (pt) * 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
US8190467B2 (en) * 2007-10-19 2012-05-29 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos

Also Published As

Publication number Publication date
SG11201401794YA (en) 2014-09-26
PE20141669A1 (es) 2014-11-08
CN103842348B (zh) 2015-08-19
GT201400067A (es) 2015-02-27
AR088082A1 (es) 2014-05-07
US20130217762A1 (en) 2013-08-22
PT2766350T (pt) 2017-05-22
AU2012321113A1 (en) 2014-03-27
EP2766350B1 (en) 2017-04-05
CA2847889A1 (en) 2013-04-18
ECSP14013305A (es) 2014-05-31
US8658693B2 (en) 2014-02-25
JP6002228B2 (ja) 2016-10-05
DOP2014000075A (es) 2014-06-01
TN2014000136A1 (en) 2015-07-01
CO6910195A2 (es) 2014-03-31
EA201490519A1 (ru) 2014-09-30
PL2766350T3 (pl) 2017-08-31
EP2766350A1 (en) 2014-08-20
ES2626820T3 (es) 2017-07-26
JP2014530818A (ja) 2014-11-20
CN103842348A (zh) 2014-06-04
AP2014007548A0 (en) 2014-03-31
CR20140156A (es) 2014-05-16
BR112014008668A2 (pt) 2017-04-25
PH12014500808A1 (en) 2019-07-03
AU2012321113B2 (en) 2015-07-09
MX2014004558A (es) 2014-08-01
WO2013055577A1 (en) 2013-04-18
TW201329026A (zh) 2013-07-16
CL2014000895A1 (es) 2014-08-22
TWI449686B (zh) 2014-08-21
IL231440A0 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CN103842348B (zh) 选择性雄激素受体调节剂
EP2970156B1 (en) Substituted benzoxazoles and methods of use thereof
EP3166939B1 (en) Therapeutic compounds and methods of use thereof
JP6038297B2 (ja) Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用
CA3102848A1 (en) Novel salts and crystals
CA2914723A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
TW201329050A (zh) Ｔｒｐｖ１拮抗劑
WO2015028409A1 (de) 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP2019532077A (ja) 治療用化合物及びその使用方法
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
CN115427410B (zh) 酰胺或者磺酰胺类衍生物及其应用
EP3573963A1 (en) Nrf2 activator
AU2012384456B2 (en) Novel cholecystokinin receptor ligands
TW202003490A (zh) 治療性化合物及其使用方法
JP7766782B2 (ja) ビタミンｄ誘導体の結晶又はその溶媒和物の結晶
WO2023059610A1 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2014015125A1 (en) Fused aminodihydrothiazine derivative salts and uses thereof
CN104203922A (zh) 螺乙内酰脲化合物及其作为选择性雄激素受体调节剂的用途
TWI738162B (zh) 稠合三環氘代衍生物及其組合物和用途
WO2013014627A1 (en) Pyrazoline derivatives and their use as selective androgen receptor modulators
KR102534043B1 (ko) Cns 장애의 치료에서 사용하기 위한 3.알파.-에타인일, 3.베타.-하이드록시-5.알파.-프레그난-20-옥심
HK40056233A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
WO2019165290A1 (en) Pyridine-sulfonamide compounds and their use against pain and related conditions
KR20150126689A (ko) 치환된 벤족사졸 및 이의 사용 방법
HK1217428B (en) Substituted benzoxazoles and methods of use thereof

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20140409

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140409

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150812

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160204

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee